96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day vs triple therapy in patients with suppressed viraemia: virological success and non-HIV related morbidity evaluation-Reference-Cited by-同舟云学术

96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day vs triple therapy in patients with suppressed viraemia: virological success and non-HIV related morbidity evaluation

Published:2020-01-02 Issue:1 Volume:21 Page:34-43
ISSN:2578-7489
Container-title:HIV Research & Clinical Practice
language:en
Short-container-title:HIV Research & Clinical Practice

Author:

Di Cristo Valentina¹,Adorni Fulvio²,Maserati Renato³,Annovazzi Lodi Marco³,Bruno Giuseppe⁴,Maggi Paolo⁴,Volpe Anna⁴,Vitiello Paola⁵,Abeli Clara⁵,Bonora Stefano⁶,Ferrara Micol⁶,Cossu Maria Vittoria⁷,Oreni Maria Letizia¹,Colella Elisa¹,Rusconi Stefano¹^ORCID

Affiliation:

1. Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan, Italy;

2. ITB‐CNR, Segrate, MI, Italy;

3. Infectious Diseases Unit, Policlinico San Matteo Foundation, IRCCS, Pavia, Italy;

4. Infectious Diseases Unit, University of Bari, Bari, Italy;

5. Infectious Diseases Unit, ASST Valle Olona, Ospedale di Circolo, Busto Arsizio, VA, Italy;

6. Infectious Diseases Unit, University of Turin, Turin, Italy;

7. First Infectious Diseases Unit, ASST Fatebenefratelli‐Sacco, Milan, Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Infectious Diseases

Link

https://www.tandfonline.com/doi/pdf/10.1080/25787489.2020.1734752

Reference25 articles.

1. Linee Guida 2017 sull’utilizzo dei farmaci antiretrovirali e sulla gestione diagnostica-clinica delle persone con infezione da HIV-1. 2017. http://www.salute.gov.it/imgs/C_17_pubblicazioni_2696_allegato.pdf

2. European AIDS clinical society. Guidelines: clinical management of treatment of HIV infected adults in Europe, 2018. http://www.eacsociety.org/files/2018_guidelines-9.1-english.pdf

3. BHIVA (British HIV Association). Treatment of HIV-1-positive adults with antiretroviral therapy guidelines. https://www.bhiva.org/guidelines

4. Metabolic Syndrome, Diabetes, and Cardiovascular Risk in HIV

5. The Metabolic Syndrome and HIV Infection

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HIV-1 protease inhibitors with a P1 phosphonate modification maintain potency against drug-resistant variants by increased interactions with flap residues;European Journal of Medicinal Chemistry;2023-09

2. Selection of HIV-1 for resistance to fifth-generation protease inhibitors reveals two independent pathways to high-level resistance;eLife;2023-03-15

3. Effectiveness and Safety Analysis of PIs/r Based Dual Therapy in Treatment-Naïve, HIV/AIDS Patients: A Network Meta Analysis of Randomized Controlled Trials;Frontiers in Pharmacology;2022-03-04

4. Dolutegravir Plus Lamivudine Two-Drug Regimen: Safety, Efficacy and Diagnostic Considerations for Its Use in Real-Life Clinical Practice—A Refined Approach in the COVID-19 Era;Diagnostics;2021-04-29

5. Risks and benefits of reducing the number of drugs to treat HIV-1 infection;Expert Opinion on Drug Safety;2021-02-24